AbbVie successfully faces off with Amgen in patent interference involving buffer-free antibody formulations
Clients AbbVie, Inc.
Jones Day represented AbbVie, Inc. in a patent interference against Amgen, Inc. before the PTAB involving the parties' applications/patents generally related to buffer-free antibody formulations, including formulations to adalimumab, marketed as Humira®. On December 15, 2017, Gokarn (Amgen) conceded priority as to the invention in dispute. As a result, on December 20, 2017, the PTAB entered judgement against Gokarn (Amgen) in favor of Fraunhofer (AbbVie).
Fraunhofer (AbbVie) v. Gokarn (Amgen), Patent Interference No. 106,057 (PTAB 2016)